Company intelligence / Profile preview

Beijing Double-Crane Runchuang Technology Co., Ltd.

Beijing, Beijing, Chinadcpc.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company is an active subsidiary focused on small molecule drug development targeting oncology, infectious diseases, and metabolic disorders. Its most advanced programs are in early clinical stages with at least one program reaching Phase I/II trials for ovarian cancer and another at IND stage for solid tumors. Published research includes novel NDM‑1 inhibitors to combat multidrug-resistant bacterial infections.

Therapeutic areas: OncologyEndocrinologyInfectious Diseases
Modalities: Small molecule drugsPotentially others (see pipeline)
Industry: Biotech

Drug pipeline

2 assets

DC10190

Unknown

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Beijing Double-Crane Runchuang Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Double-Crane Runchuang Technology Co., Ltd..

Explore the full profile